netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Section
Notes:

Chapter review date:

 Useful Links
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
02.01 Positive inotropic drugs (0,0)
02.01.01 Cardiac glycosides (1,0)
Digoxin-specific antibody (1,0)
02.01.02 Phosphodiesterase type-3 inhibitors (1,1)
02.02 Diuretics (0,0)
02.02.01 Thiazides and related diuretics (4,4)
02.02.02 Loop diuretics (2,1)
02.02.03 Potassium-sparing diuretics and aldosterone antagonists (1,1)
Aldosterone antagonists (2,0)
02.02.04 Potassium-sparing diuretics with other diuretics (0,10)
02.02.05 Osmotic diuretics (1,0)
02.02.06 Mercurial diuretics (0,0)
02.02.07 Carbonic anhydrase inhibitors (0,0)
02.02.08 Diuretics with potassium (0,5)
02.03 Anti-arrhythmic drugs (0,0)
02.03.01 Management of arrhythmias (0,0)
02.03.02 Drugs for arrhythmias (0,1)
Supraventricular arrhythmias (2,0)
Supraventricular and ventricular arrhythmias (4,1)
Ventricular arrhythmias (2,0)
02.04 Beta-adrenoceptor blocking drugs (9,14)
02.05 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs (1,0)
02.05.01 Vasodilator antihypertensive drugs (11,4)
02.05.02 Centrally acting antihypertensive drugs (3,0)
02.05.03 Adrenergic neurone blocking drugs (1,0)
02.05.04 Alpha-adrenoceptor blocking drugs (2,3)
Phaeochromocytoma (2,0)
02.05.05 Drugs affecting the renin-angiotensin system (0,1)
Heart Failure (0,0)
02.05.05.01 Angiotensin-converting enzyme inhibitors (ACE inhibitors) (5,16)
02.05.05.02 Angiotensin-II receptor antagonists (2,7)
02.05.05.03 Renin inhibitors (1,1)
02.06 Nitrates, calcium-channel blockers, and potassium-channel activators (0,0)
Angina (0,0)
02.06.01 Nitrates (2,8)
02.06.02 Calcium-channel blockers (10,24)
02.06.03 Other anitanginal drugs (3,0)
02.06.04 Peripheral vasodilators and related drugs (2,3)
Other preparations used in peripheral vascular disease (0,1)
02.07 Sympathomimetics (0,0)
02.07.01 Inotropic sympathomimetics (4,0)
02.07.02 Vasoconstrictor sympathomimetics (6,0)
02.07.03 Cardiopulmonary resuscitation (1,0)
02.08 Anticoagulants and protamine (0,0)
02.08.01 Parenteral anticoagulants (1,0)
Heparin (1,0)
Low molecular weight heparins (3,1)
Heparinoids (1,0)
Hirudins (1,0)
Heparin flushes (1,0)
Epoprostenol (1,0)
Fondaparinux (1,0)
02.08.02 Oral anticoagulants (7,0)
Atrial Fibrillation (0,0)
VTE Prophylaxis (0,0)
02.08.03 Agents to reverse the effects of anticoagulants (3,0)
02.09 Antiplatelet drugs (8,4)
02.10 Stable angina, acute coronary syndromes, and fibrinolysis (0,0)
02.10.01 Management of stable angina and acute coronary syndromes (0,0)
02.10.02 Fibrinolytic drugs (4,2)
02.11 Antifibrinolytic drugs and haemostatics (3,1)
Blood-related products (13,0)
02.12 Lipid-regulating drugs (2,1)
Bile acid sequestrants (1,1)
Ezetimibe (2,0)
Fibrates (2,2)
Statins (5,2)
Nicotinic acid group (0,3)
Omega-3 fatty acid compounds (0,2)
PCSK9 inhibitors (0,0)
Other lipid modifying agents (0,0)
02.13 Local sclerosants (2,0)
netFormulary